Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
Upturn AI SWOT - About
GRAIL, LLC (GRAL)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
09/15/2025: GRAL (4-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Above Average Performance
These Stocks/ETFs, based on Upturn Advisory, frequently surpass the market, reflecting reliable and trustworthy advice.
Number of Analysts
4 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $40.5
1 Year Target Price $40.5
| 1 | Strong Buy |
| 0 | Buy |
| 3 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 72.76% | Avg. Invested days 39 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  5.0 | Stock Returns Performance  4.0 |
| Profits based on simulation | Last Close 09/15/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 1.37B USD | Price to earnings Ratio - | 1Y Target Price 40.5 |
Price to earnings Ratio - | 1Y Target Price 40.5 | ||
Volume (30-day avg) 4 | Beta - | 52 Weeks Range 12.33 - 63.99 | Updated Date 09/14/2025 |
52 Weeks Range 12.33 - 63.99 | Updated Date 09/14/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -11.71 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -368.15% |
Management Effectiveness
Return on Assets (TTM) -11.81% | Return on Equity (TTM) -17.68% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 830668273 | Price to Sales(TTM) 10.21 |
Enterprise Value 830668273 | Price to Sales(TTM) 10.21 | ||
Enterprise Value to Revenue 6.19 | Enterprise Value to EBITDA - | Shares Outstanding 36047800 | Shares Floating 24181224 |
Shares Outstanding 36047800 | Shares Floating 24181224 | ||
Percent Insiders 13.81 | Percent Institutions 73.53 |
Upturn AI SWOT
GRAIL, LLC
Company Overview
History and Background
GRAIL was founded in 2016 with the goal of detecting cancer early using blood tests. Initially incubated within Illumina, it later spun out as a separate company. A significant milestone was the development and commercialization of Galleri, its multi-cancer early detection (MCED) test. Illumina attempted to reacquire GRAIL, but regulatory hurdles led to a divestiture order.
Core Business Areas
- Early Cancer Detection: GRAIL's primary focus is on developing and commercializing multi-cancer early detection (MCED) tests. These tests aim to identify multiple types of cancer through a single blood draw, enabling earlier diagnosis and treatment.
- Genomic Sequencing: Leveraging genomic sequencing technologies to analyze cell-free DNA in blood samples for cancer signals.
- Clinical Research: Conducting clinical trials to validate and improve the performance of its cancer detection tests.
Leadership and Structure
GRAIL is led by CEO Bob Ragusa. The company has a functional organizational structure with departments dedicated to research and development, clinical operations, commercialization, and regulatory affairs.
Top Products and Market Share
Key Offerings
- Galleri: Galleri is GRAIL's flagship MCED test. It analyzes DNA in the blood to detect signals associated with over 50 types of cancer. While precise market share is challenging to ascertain due to the nascent MCED market, Galleri is a leading offering. Competitors include Exact Sciences (Guardant Health is also a competitor that is emerging in the market). Revenue information specific to Galleri is not publicly available following divestiture, but it is estimated to be in the range of $50-100 million.
Market Dynamics
Industry Overview
The industry is focused on the early detection of cancer. There is growing investment in companies that develop technology like this to identify cancer early, as this is thought to yield better outcomes for patients.
Positioning
GRAIL is positioned as a leader in the MCED market. Its competitive advantage lies in its proprietary genomic sequencing technology, large-scale clinical validation studies, and the comprehensive cancer coverage of Galleri.
Total Addressable Market (TAM)
The total addressable market (TAM) for multi-cancer early detection tests is estimated to be $47 billion. GRAIL is striving for market leadership in a rapidly expanding industry.
Upturn SWOT Analysis
Strengths
- Proprietary genomic sequencing technology
- Large-scale clinical validation studies
- Comprehensive cancer coverage
- Strong intellectual property portfolio
- First mover advantage in MCED market
Weaknesses
- High cost of testing
- Limited clinical data for specific cancer types
- Regulatory uncertainty
- Reimbursement challenges
- Dependence on Illumina's sequencing technology
Opportunities
- Expanding clinical applications
- Improving test performance
- Securing regulatory approvals
- Establishing reimbursement pathways
- Partnering with healthcare providers
Threats
- Competition from other MCED developers
- Technological advancements
- Changes in regulatory landscape
- Economic downturn
- Negative publicity
Competitors and Market Share
Key Competitors
- EXAS
- GH
Competitive Landscape
GRAIL has a strong early mover advantage, however it also faces threats from Exact Sciences (EXAS), Guardant Health (GH), and other emerging competitors in the MCED market. Its success depends on continued technological advancements and effective commercialization.
Growth Trajectory and Initiatives
Historical Growth: GRAIL experienced rapid growth prior to its acquisition by Illumina, fueled by investment in its technology and the commercialization of Galleri. Post-divestiture, the company is focused on expanding the use of Galleri and securing regulatory approvals.
Future Projections: Future growth depends on the successful expansion of Galleri, obtaining regulatory approvals, and securing reimbursement. Analyst estimates are unavailable due to the company's private status.
Recent Initiatives: Recent initiatives include expanding commercial partnerships with healthcare providers, conducting additional clinical trials to support the use of Galleri, and working with regulatory agencies to obtain approvals.
Summary
GRAIL is a key player in the emerging MCED market with the potential to transform cancer detection. Their primary focus is on the continued development and commercialization of their Galleri test. While they have a strong technological position, the cost of testing and regulatory considerations need to be addressed for long-term success. GRAIL needs to also remain focused on continued research to maintain leadership over other companies in the space. With growing competition, they need to focus on clinical utility to maintain market share.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company website
- Industry reports
- Analyst estimates (pre-divestiture)
- News articles
- SEC filings (where applicable, pre-divestiture)
Disclaimers:
The information provided is based on publicly available data and is for informational purposes only. It should not be considered investment advice. Market share data is estimated and may vary. Financial data is limited due to the company's private status.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About GRAIL, LLC
Exchange NASDAQ | Headquaters Menlo Park, CA, United States | ||
IPO Launch date 2024-06-25 | CEO & Director Mr. Robert P. Ragusa | ||
Sector Healthcare | Industry Diagnostics & Research | Full time employees 1000 | Website https://grail.com |
Full time employees 1000 | Website https://grail.com | ||
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, it develops minimal residual disease post-diagnostic tests. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.